FORESEE PHARMACEUTICALS CO.,LTD

FORESEE PHARMACEUTICALS CO., LTD is a Manufacturer.

Company Introduction:

FORESEE PHARMACEUTICALS CO., LTD is a leading clinical-stage biopharmaceutical company based in Taiwan. The company is dedicated to developing innovative drug delivery systems and therapeutics for diseases with unmet medical needs. Foresee Pharmaceuticals leverages its proprietary technology platforms to create long-acting injectable drugs, aiming to improve patient compliance and treatment outcomes. Their pipeline includes advanced programs in areas such as prostate cancer, acromegaly, and other endocrine-related disorders. With a strong focus on research and development, Foresee Pharmaceuticals is committed to transforming patient care through novel and effective pharmaceutical solutions.

FORESEE PHARMACEUTICALS CO.,LTD

Marketed Product:

Product Name: Camcevi (FP-001)

Indication: Advanced Prostate Cancer

Description: A ready-to-use, 6-month leuprolide mesylate subcutaneous injection. It is approved and marketed in the United States, Europe, and Taiwan for the treatment of advanced prostate cancer.

Pipeline Products:

Product Name: FP-001 (6-month formulation)

Indication: Endometriosis, Uterine Fibroids, Central Precocious Puberty

Development Status: Clinical development/Regulatory submission for these indications in various regions.

Description: A long-acting, ready-to-use leuprolide mesylate subcutaneous injection.

Product Name: FP-002 (3-month formulation)

Indication: Prostate Cancer, Endometriosis, Uterine Fibroids, Central Precocious Puberty

Development Status: Phase 3 completed for prostate cancer; clinical development for other indications.

Description: A 3-month leuprolide mesylate subcutaneous injection.

Product Name: FP-004 (1-month formulation)

Indication: Prostate Cancer, Endometriosis, Uterine Fibroids, Central Precocious Puberty

Development Status: Phase 1 completed.

Description: A 1-month leuprolide mesylate subcutaneous injection.

Product Name: FP-005

Indication: Adrenal Insufficiency

Development Status: Preclinical.

Product Name: FP-006

Indication: Type 2 Diabetes

Development Status: Preclinical.

Product Name: FP-008

Indication: Pain/Inflammation

Development Status: Preclinical.